Alfacell Corp., of Bloomfield, N.J., said it received U.S. Patent No. 6,175,003 titled "Nucleic Acids Encoding Ribonucleases and Methods of Making Them." It covers gene sequences of Onconase.

Applied Gene Technologies Inc., of San Diego, said it received U.S. Patent No. 6,187,566 titled "Method of Labeling a Nucleic Acid Amplicon With Simultaneous Contamination Prevention." It covers Tessera Array Technology, a nonamplification process involving the labeling of unpurified nucleic acid samples with luminescent compounds followed by hybridization with probes for the detection of the sequence of the target market genes for infectious diseases or cancer.

Avigen Inc., of Alameda, Calif., said it received U.S. Patent No. 6,200,560. It covers treatment of hemophilia A using AAV vectors.

BioTransplant Inc., of Charlestown, Mass., said it received U.S. Patent No. 6,190,861 titled "Molecular Sequence of Swine Retrovirus and Methods of Use," through a license from Massachusetts General Hospital. It covers a method for screening cells or tissue for the presence of retroviruses in the porcine genome.

Coley Pharmaceutical Group, of Wellesley, Mass., said it received U.S. Patent No. 6,194,388. It covers CpG immune stimulants.

Collateral Therapeutics Inc., of San Diego, said it received U.S. Patent No. 6,183,961 titled "Methods and Compositions For Regulating Cell Cycle Progression." It covers a gene involved in regulating the human cell cycle.

Copernicus Therapeutics Inc., of Cleveland, said it received U.S. Patent No. 6,200,801 through a license from Case Western Reserve University. It covers serpin enzyme complex receptor-mediated gene transfer.

Cytos Biotechnology AG, of Zurich, Switzerland, said it received U.S. Patent No. 6,197,502 titled "Expression Cloning Process for the Discovery, Characterization, and Isolation of Genes Encoding Polypeptides with a Predetermined Property." It broadly covers Cytos' key technology for protein discovery and characterization.

Enzon Inc., of Piscataway, N.J., said it received U.S. Patent No. 6,172,046. It covers a method of treatment for hepatitis C virus-infected patients by administration of peginterferon alfa-2b and ribavirin.